Evidence map›Paper›PMID 28619075›Full record

ArticleBMC complementary and alternative medicine2017

Anti-inflammatory effect of Chang-An-Shuan on TNBS-induced experimental colitis in rats.

Hong Mi, Feng-Bin Liu, Hai-Wen Li, Jiang-Tao Hou, Pei-Wu Li

Open access · goldAbstract read
In one paragraph

Article in BMC complementary and alternative medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Promising protective treatment potential of endophytic bacteriumJournal of Zhejiang University. Science. B · 2025
    Article
  3. Chang'an decoction alleviates endoplasmic reticulum stress by regulating mitofusin 2 to improve colitis.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024
    Article
  4. Efficacy of active ingredients in Qingdai on ulcerative colitis: a network pharmacology-based evaluation.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023
    Article
  5. Biomedical optics express · 2022
    Article
  6. Article
  7. Review
  8. Article
  9. Antioxidant and Anti-Inflammatory Properties of aAntioxidants (Basel, Switzerland) · 2019
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hong MiDepartment of Gastroenterology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Feng-Bin LiuDepartment of Gastroenterology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. liufb163@163.com.
Hai-Wen LiFirst School of Clinic Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Jiang-Tao HouDepartment of Gastroenterology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Pei-Wu LiDepartment of Gastroenterology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
First Affiliated Hospital of Guangzhou University of Chinese Medicine · CNGuangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory bowel disease (IBD), denominated by Crohn's disease and ulcerative colitis, is often associated with abdominal pain, diarrhea and bloody stool. The standard protocols for treating colitis conditions are not satisfactory; thus, complementary and alternative medicines have been increasingly accepted by IBD sufferers worldwide. In this study, we aimed to elucidate the anti-inflammatory effect of Chang-An-Shuan (CAS), a 6-herb Chinese medicinal formula, on 2, 4, 6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in rats and the underlying mechanisms.

methodsSprague-Dawley rats were administered with rectal gavage of 2.5% TNBS in 50% ethanol for the induction of experimental colitis which is considered as a model for Crohn's disease. Upon the TNBS induction, rats were given CAS at 0.5 g/kg/day or 5 g/kg/day for 10 days. The application of salicylazosulfapyridine (0.5 g/kg/day) was served as a positive reference drug for the colitis condition. The efficacy and mechanistic action of CAS were evaluated by means of histopathological and biochemical approaches such as histological staining, real-time polymerase chain reaction, Western blotting analysis and enzyme-linked immunosorbent assay.

resultsOral administration of CAS at 5 g/kg/day, but not 0.5 g/kg/day, significantly ameliorated the severity of TNBS-induced colitis as evidenced by the reduced loss of body weight, alleviated diarrhea and decreased bloody stool. While lowering the disease activity index, the administration of CAS lessened mucosal lesions thus mucosal integrity of the colitis rats was notably improved. Further, the CAS treatment also significantly suppressed the mRNA and protein levels of pro-inflammatory cytokines, namely interleukin-1β and tumor necrosis factor-α while enhancing the level of anti-inflammatory cytokine IL-10 in the TNBS-treated rats. Importantly, the ameliorative effect of CAS was related to an inhibition of the nuclear factor-κB (NF-κB) signaling pathway by downregulating the expression levels of NF-κBp-65, p-38 and p-AKT.

conclusionsWe suggest that CAS is a potential alternative remedial approach for treating IBD conditions, and the anti-inflammatory effect of CAS is associated with the down-regulation of the NF-κB signaling pathway and the balanced production of pro- and anti-inflammatory cytokines.

Indexed as

AnimalsAnti-Inflammatory AgentsColitisDrugs, Chinese HerbalHumansInterleukin-10Interleukin-1betaMaleNF-kappa BRatsRats, Sprague-DawleyTrinitrobenzenesulfonic AcidAnti-Inflammatory AgentsDrugs, Chinese HerbalInterleukin-10Interleukin-1betaNF-kappa BTrinitrobenzenesulfonic AcidChang-An-ShuanInterleukin-1βNuclear factor-κBTumor necrosis factor-αUlcerative colitis

Identifiers

PMID28619075
PMCPMC5473004
OpenAlexW2626223203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.